His research interests include: optimizing current therapies and finding new therapeutical approaches to reduce the progressive loss of cardiovascular and renal function, both in diabetic and non-diabetic renal disease. The role of albuminuria/proteinuria and microalbuminuria as biomar- kers for cardiac and renal disease progression has been his particular interest, not only in trying to establish the independent causal role of albumin leakage in renal and CVD progression, but also to establish intervention strategies that lower albuminuria/proteinuria with the supposed organ protective results. In his albuminuria quest he initiated large cohort studies such as PREVEND (in general population) and GIANTT (type 2 diabetes), and is involved in the leadership of several clinical trials on preventing diabetic car- diovascular and renal disease progression such as RENAAL (angiotensin II receptor antagonist), PLANET (statin), TREAT (darbepoetin), VITAL (vitamin D), SUN (sulodex- ide), ALTITUDE (renin-inhibition), CANVAS (SGLT2-in- hibition), RADAR (atrasentan) and BEACON (bardoxolone). biographic and disclosure information http://www.kidney-international.org & 2012 KDIGO Unraveling the reasons for individual therapy resistance and creating a response score to evaluate the total effect of drugs are the topics that he judges to be of important focus for the next decade. He has authored more than 440 international scientific publications and more than 60 book chapters, and received the Lennart Hansson Memorial Lecture Award from the European Society of Hypertension, the International Distinguished Medal from the US National Kidney Foundation, and a special lecture award from the Japanese Society of Nephrology. Advisor/Consultant: Abbott; Amgen; Astellas; AstraZeneca; Bristol-Myers Squibb; HemoCue; Johnson & Johnson; Merck Sharp & Dohme; Novartis; Reata; Takeda; Vitae Toshiro Fujita, MD, is Professor and Chairman of the Department of Internal Medicine and Chief of the Depart- ment of Nephrology and Endocrinology at the University of Tokyo. 